{"organizations": [], "uuid": "b2b248eec39b0a92688b77d51ea74e60f4637ca5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180521.html", "section_title": "Archive News &amp; Video for Monday, 21 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-genentechs-announces-results-from/brief-genentechs-announces-results-from-phase-iii-haven-3-study-evaluating-hemlibra-prophylaxis-idUSFWN1SS00F", "country": "US", "domain_rank": 408, "title": "BRIEF-Genentech's Announces results from Phase III Haven 3 study evaluating Hemlibra prophylaxis", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-05-21T14:07:00.000+03:00", "replies_count": 0, "uuid": "b2b248eec39b0a92688b77d51ea74e60f4637ca5"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-genentechs-announces-results-from/brief-genentechs-announces-results-from-phase-iii-haven-3-study-evaluating-hemlibra-prophylaxis-idUSFWN1SS00F", "ord_in_thread": 0, "title": "BRIEF-Genentech's Announces results from Phase III Haven 3 study evaluating Hemlibra prophylaxis", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "genentech", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 21 (Reuters) -\n* GENENTECHâ€™S HEMLIBRA (EMICIZUMAB-KXWH) REDUCED TREATED BLEEDS BY 96 PERCENT COMPARED TO NO PROPHYLAXIS IN PHASE III HAVEN 3 STUDY IN HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS\n* GENENTECH - HEMLIBRA REDUCED TREATED BLEEDS BY 96 PERCENT COMPARED TO NO PROPHYLAXIS IN PHASE III HAVEN 3 STUDY IN HEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS\n* GENENTECH- DATA FROM BOTH HAVEN 3 AND HAVEN 4 STUDIES ARE BEING SUBMITTED TO HEALTH AUTHORITIES AROUND WORLD FOR APPROVAL CONSIDERATION Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-21T14:07:00.000+03:00", "crawled": "2018-05-22T19:32:27.009+03:00", "highlightTitle": ""}